Evidence map›Paper›PMID 33896316›Full record

ArticleExpert review of vaccines2021

The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?

Md Kamal Hossain, Majid Hassanzadeganroudsari, Vasso Apostolopoulos

Abstract readEditorial
In one paragraph

Article in Expert review of vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Current computer-aided drug design · 2025
    Article
  6. Design, Synthesis and Biological Exploration of NovelInternational journal of molecular sciences · 2024
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!Acta bio-medica : Atenei Parmensis · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Md Kamal HossainInstitute for Health and Sport, Victoria University, Melbourne, VIC, Australia.ORCID 0000-0001-5173-8994
Majid HassanzadeganroudsariInstitute for Health and Sport, Victoria University, Melbourne, VIC, Australia.ORCID 0000-0002-3241-6444
Vasso ApostolopoulosInstitute for Health and Sport, Victoria University, Melbourne, VIC, Australia.ORCID 0000-0001-6788-2771

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 VaccinesCOVID-19HumansSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CoronavirusCOVID-19mutant strainmutant virusSARS-CoV-2vaccinevariant virus

Identifiers

PMID33896316
PMCPMC8074646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.